Cargando…

Delafloxacin: Place in Therapy and Review of Microbiologic, Clinical and Pharmacologic Properties

Delafloxacin (formerly WQ-3034, ABT492, RX-3341) is a novel fluoroquinolone chemically distinct from currently marketed fluoroquinolones with the absence of a protonatable substituent conferring a weakly acidic character to the molecule. This property results in increased intracellular penetration a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jorgensen, Sarah C. J., Mercuro, Nicholas J., Davis, Susan L., Rybak, Michael J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5986682/ https://www.ncbi.nlm.nih.gov/pubmed/29605887 http://dx.doi.org/10.1007/s40121-018-0198-x

Ejemplares similares

Delafloxacin: design, development and potential place in therapy
por: Candel, Francisco Javier, et al.
Publicado: (2017)

Clinical Pharmacology of Delafloxacin in Patients With Hepatic Impairment
por: Hoover, Randall, et al.
Publicado: (2016)

Updated Review on Clinically-Relevant Properties of Delafloxacin
por: Turban, Adrien, et al.
Publicado: (2023)

Delafloxacin in Acute Bacterial Skin and Skin Structure Infections
por: Corey, G Ralph, et al.
Publicado: (2019)

Efficacy of Delafloxacin versus Moxifloxacin against Bacterial Respiratory Pathogens in Adults with Community-Acquired Bacterial Pneumonia (CABP): Microbiology Results from the Delafloxacin Phase 3 CABP Trial
por: McCurdy, Sandra, et al.
Publicado: (2020)

Delafloxacin: First Global Approval
por: Markham, Anthony
Publicado: (2017)

Delafloxacin: A Review in Acute Bacterial Skin and Skin Structure Infections
por: Scott, L. J.
Publicado: (2020)

Correction to: Delafloxacin: First Global Approval
por: Markham, Anthony
Publicado: (2018)

Delafloxacin Pharmacokinetics in Subjects With Varying Degrees of Renal Function
por: Hoover, Randall K., et al.
Publicado: (2017)

2230. Analysis of the Microbiological Data from the Delafloxacin (DLX) Phase 3 Community-acquired Bacterial Pneumonia (CABP) Trial
por: McCurdy, Sandra, et al.
Publicado: (2019)

Correction to: Delafloxacin: A Review in Acute Bacterial Skin and Skin Structure Infections
por: Scott, L. J.
Publicado: (2020)

Profile of a Novel Anionic Fluoroquinolone—Delafloxacin
por: Tulkens, Paul M, et al.
Publicado: (2019)

Safety of Delafloxacin: Focus on Adverse Events of Special Interest
por: Lodise, Thomas, et al.
Publicado: (2018)

Efficacy of Delafloxacin against the Biothreat Pathogen Burkholderia pseudomallei
por: McCurdy, Sandra, et al.
Publicado: (2021)

Delafloxacin, Finafloxacin, and Zabofloxacin: Novel Fluoroquinolones in the Antibiotic Pipeline
por: Kocsis, Béla, et al.
Publicado: (2021)

P41 Use of delafloxacin in osteomyelitis: a case report
por: Vidwans, Madhuri, et al.
Publicado: (2023)

54. Microbiologic Characterization and Antibacterial Use in Hospitalized Adults with covid-19 Infection
por: Chapin, Ryan, et al.
Publicado: (2020)

629. Emergence and Clonal Spread of Delafloxacin-Resistant S. aureus in Brooklyn, NY
por: Malik, Saquib, et al.
Publicado: (2019)

In Vitro Activity of Delafloxacin and Finafloxacin against Mycoplasma hominis and Ureaplasma Species
por: Kong, Yingying, et al.
Publicado: (2022)

Evaluation of Delafloxacin against a Burkholderia pseudomallei Efflux Mutant Panel
por: McCurdy, Sandra P., et al.
Publicado: (2022)

Chemical structure and pharmacokinetics of novel quinolone agents represented by avarofloxacin, delafloxacin, finafloxacin, zabofloxacin and nemonoxacin
por: Kocsis, Bela, et al.
Publicado: (2016)

Human Target Attainment Probabilities for Delafloxacin against Escherichia coli and Pseudomonas aeruginosa
por: Hoover, Randall, et al.
Publicado: (2017)

Pathogen-Specific Clinical Trials: A New Paradigm in Clinical Trials for Multidrug-Resistant Organisms
por: Jorgensen, Sarah C. J., et al.
Publicado: (2018)

Activity of Delafloxacin and Comparator Fluoroquinolones against Multidrug-Resistant Pseudomonas aeruginosa in an In Vitro Cystic Fibrosis Sputum Model
por: Craddock, Vaughn D., et al.
Publicado: (2023)

In Vitro Activity of Delafloxacin and Microbiological Response against Fluoroquinolone-Susceptible and Nonsusceptible Staphylococcus aureus Isolates from Two Phase 3 Studies of Acute Bacterial Skin and Skin Structure Infections
por: McCurdy, S., et al.
Publicado: (2017)

Clinical Utility of Lefamulin: If Not Now, When?
por: Mercuro, Nicholas J., et al.
Publicado: (2020)

Development of Lipomer Nanoparticles for the Enhancement of Drug Release, Anti-Microbial Activity and Bioavailability of Delafloxacin
por: Anwer, Md. Khalid, et al.
Publicado: (2020)

2378. Resolution of Signs and Symptoms (S&S) of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) With Delafloxacin (DLX) IV/Oral Therapy
por: Pullman, John, et al.
Publicado: (2018)

Emerging treatment options for acute bacterial skin and skin structure infections: focus on intravenous delafloxacin
por: Righi, Elda, et al.
Publicado: (2018)

In Vitro Activity of Delafloxacin against Contemporary Bacterial Pathogens from the United States and Europe, 2014
por: Pfaller, M. A., et al.
Publicado: (2017)

Community-Acquired Bacterial Pneumonia—Changing Epidemiology, Resistance Patterns, and Newer Antibiotics: Spotlight on Delafloxacin
por: Sharma, Roopali, et al.
Publicado: (2020)

Activity of Delafloxacin and Levofloxacin against Stenotrophomonas maltophilia at Simulated Plasma and Intrapulmonary pH Values
por: Vialichka, Alesia, et al.
Publicado: (2022)

The in vitro activity of delafloxacin and comparator agents against bacterial pathogens isolated from patients with cancer
por: Gerges, Bahgat, et al.
Publicado: (2023)

Clinical Pharmacology of Bacteriophage Therapy: A Focus on Multidrug-Resistant Pseudomonas aeruginosa Infections
por: Holger, Dana, et al.
Publicado: (2021)

1019. Treatment Outcomes for Enterococcus faecium Bacteremia in Solid-Organ Transplant Patients: Implications for Daptomycin
por: Mercuro, Nicholas J, et al.
Publicado: (2018)

2373. Evaluation of Delafloxacin Activity and Treatment Outcome for Phase 3 Acute Bacterial Skin and Skin Structure Infection Clinical Trial Anaerobic Isolates
por: Shortridge, Dee, et al.
Publicado: (2018)

The Efficacy and Adverse Events of Delafloxacin for Treating Acute Bacterial Skin and Skin Structure Infections: A Systematic Review and Meta-Analysis
por: Tanvir, Syed Bilal, et al.
Publicado: (2020)

The efficacy and adverse events of delafloxacin in the treatment of acute bacterial infections: A systematic review and meta-analysis of randomized controlled trials
por: He, Rong, et al.
Publicado: (2022)

Analysis of Pooled Phase 3 Safety Data for Delafloxacin in Acute Bacterial Skin and Skin Structure Infections
por: Bassetti, Matteo, et al.
Publicado: (2019)

Analysis of Pooled Phase III Efficacy Data for Delafloxacin in Acute Bacterial Skin and Skin Structure Infections
por: Giordano, Philip A, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_gbec091f8dv73b2vp5ecg1n6o3